Fennec Pharmaceuticals Inc FENC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $10.63
- Day Range
- $10.57–10.86
- 52-Week Range
- $5.65–13.25
- Bid/Ask
- $10.21 / $10.73
- Shares Outstanding
- 35.07M
- Market Cap
- $375.57M
- Volume/Avg
- 93,238 / 191,167
Key Statistics
- Price/Earnings (Normalized)
- 64.57
- Price/Sales
- 6.01
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 35
- Website
- https://www.fennecpharma.com
Valuation
|
Metric
|
FENC
|
|---|---|
Price/Earnings (Normalized) | 64.57 |
Price/Book Value | 8.77 |
Price/Sales | 6.01 |
Price/Cash Flow | 69.14 |
Price/Earnings
FENC
Financial Strength
|
Metric
|
FENC
|
|---|---|
Quick Ratio | 5.21 |
Current Ratio | 5.85 |
Interest Coverage | −3.55 |
Quick Ratio
FENC
Profitability
|
Metric
|
FENC
|
|---|---|
Return on Assets (Normalized) | 10.05% |
Return on Equity (Normalized) | 30.28% |
Return on Invested Capital (Normalized) | 21.68% |
Return on Assets
FENC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%<#FM@ | LOCK|j!Nf | $128B | |||
| Moderna Inc
MRNA
| LOCK|LSm?%l | LOCK|&b | $79B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?^XZn% | LOCK|rj>% | $76B | |||
| argenx SE ADR
ARGX
| LOCK|>@&?BQp | LOCK|gf | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|K^sCp<b | LOCK|PL | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&g$Z<<^ | LOCK|kHtY | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|H>BWfHL% | LOCK|K!L$ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|F$?wj^& | LOCK|!M! | $23B | |||
| Incyte Corp
INCY
| LOCK|VNdmJW& | LOCK|Sg! | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|>jKt&P | LOCK|%y% | $14B |
United States